Type 2 diabetes
Conditions
Interventions
Dulaglutide plus basal insulin group: this group receives linagliptin once daily with basal insulin once daily and supplemental dose of regular insulin. Study term is 7 days after hospitalization.
Bas
Sponsors
Ichinomiyanishi Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Recruited patients had a known history of type 2 diabetes (T2D) with a blood glucose (BG) between 140 and 400 mg/dL and a known history of T2D for over 3 months, and were treated diet alone, any combination of oral antidiabetic agents, or low-dose insulin therapy.
Exclusion criteria
Exclusion criteria: Patients admitted to or expected to require ICU admission; Patients with basal-bolus insulin therapy, corticosteroid therapy,therapy of once weekly antidiabetic agents, clinically relevant gastrointestinal disease, impaired renal function (serum creatinine >3.0 mg/dL); and patients with a history of diabetic ketoacidosis and hyperglycemic crises pregnancy, or any mental condition rendering the subject unable to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of target glucose rage | — |
Secondary
| Measure | Time frame |
|---|---|
| mean blood glucose (BG), glycemic variability (GV), percentage of hypoglycemia, percentage of BG over 200 mg/dl, side effect | — |
Countries
Japan
Contacts
Public ContactMatsubara Akihiro
Ichinomiyanishi Hospital Research Planning Division
Outcome results
None listed